Anti-epidermal growth factor

Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000 18 904—914. [Pg.174]

Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993 85 1327-1333. [Pg.335]

Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984 44 1002-1007. [Pg.347]

DivgiCR, Welt S, Kris M, et al. Phase I and imaging trial of indium Ill-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinomas. JNatl Cancer Inst 1991 83 97-194. [Pg.347]

Cohen RB, Falcey JW, Paulter VJ, et al. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors. Proc Am Soc Clin Oncol 2000 19 1862 (abstr). [Pg.347]

Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., Jr., and Mendelsohn, J. (1993). Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 85, 1327-1333. [Pg.421]

Prewett, M., Rothman, M., Waksal, H., Feldman, M., Bander, N. H., and Hicklin, D. J. (1998). Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin. Cancer Res. 4, 2957-2966. [Pg.421]

Sokolov K, Follen M, Aaron J, et al. Real-time vital optical imaging of pancancer using anti-epidermal growth factor receptor antibodies conjugated gold nanoparticles. Cancer Res 2003 63 1999-2004. [Pg.333]

Allometric scaling has been applied to mABs (23). Duconge and co-workers conducted PK studies of anti-epidermal growth factor (EGF) receptor in mice/ ratS/ rabbitS/ and dogs after a single administration of... [Pg.483]

Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. 1996. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIPl and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56 3666-69... [Pg.224]

Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, et al. 1999. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with doc-etaxel and anti-epidermal growth factor-receptor antibody on human breast cancercell growth. Clin. Cancer Res. 5 875-81... [Pg.224]

Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, et al. 2000. Pacli-taxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6 4874-84... [Pg.224]

Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR (2007) Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther 6(4) 1230-1238... [Pg.397]

Riemer, A.B., Kurz, H., Klinger, M., Scheiner, O., Zielinski, C.C., and Jensen-Jarolim. E.. 2005. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies, J. Natl. Cancer Inst., 91, pp. 1663-1670. [Pg.200]

E. K. Rowinsky, G. H. Schwartz, J. A. Gollob, J. A. Thompson, N. J. Vogelzang, R. Figlin, R. Bukowski, N. Haas, P. Lockbaum, Y. P. Li, R. Arends, K. A. Foon, G. Schwab, and J. Dutcher, Safety, pharmacokinetics, and activity of ABX-EGF, a fuUy human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. / Clin Oncol 22(15) 3003-3015 (2004). [Pg.1028]

Meenakshi A, Ganesh V, Suresh Kumar R et al (2003) Radioimmuno targetting technetium-labeled anti-epidermal growth factor receptor monoclonal antibodies in experimental tumor models. Q J Nucl Med 47 139-144... [Pg.55]

Reist C J, Archer G E, Wikstrand C J, et al. (1997). Improved targeting of an anti-epidermal growth factor receptor variant 111 monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 57 1510-1515. [Pg.928]

Vaidyanathan G, Affleck D J, Bigner D D, et al. (2002). Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant 111 antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl. Med. Biol. 29 1-11. [Pg.928]

Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan Z. Requirement of hypoxia-inducible factor-1 alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther 2008 7 1207-1217. [Pg.46]

Gibson TB, Ranganathan A, Grothey A (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6 29-31... [Pg.294]

Masui H, Moroyama T, Mendelsohn J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Research 1986 46 5592-5598. [Pg.356]

Messersmith WA, Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer another one or the one Clinical Cancer Research 2007 13 4664-4666. [Pg.360]

Hutcheson IR, Knowlden JM, Jones HE et al. (2006) Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocr Relat Cancer 13 (Suppl 1) S89-S97... [Pg.215]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...